Status:

COMPLETED

INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA)

Lead Sponsor:

Vivencio Barrios

Collaborating Sponsors:

Bayer

Conditions:

Atrial Fibrillation and Flutter

Eligibility:

All Genders

18+ years

Brief Summary

The primary objective of this study was to determine rates of INR control of patients with nonvalvular AF daily attended in primary care in Spain. PAULA is an observational retrospective/cross-sectio...

Detailed Description

Vitamin K antagonists (VKAs) have traditionally been used for long-term prevention of thromboembolic complications in patients with atrial fibrillation (AF). Because of the variability in the dose res...

Eligibility Criteria

Inclusion

  • Patients aged ≥18 years old with
  • nonvalvular AF,
  • treated with VKAs for at least one year in primary care
  • At least 80% of INR values during the past 12 months should be available.
  • Written consent should be provided before inclusion.

Exclusion

  • Patients that do not sign or understand written consent.
  • Participating in a clinical trial in the last 12 months.

Key Trial Info

Start Date :

February 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

1524 Patients enrolled

Trial Details

Trial ID

NCT02273609

Start Date

February 1 2014

End Date

October 1 2014

Last Update

October 29 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA) | DecenTrialz